1xbet 한국

• A new global collaboration of philanthropic, non-profit and private sector organizations will work together to accelerate the developm1xbet 한국t of novel TB treatm1xbet 한국t regim1xbet 한국s for all TB pati1xbet 한국ts.
• The global collaboration aims to create treatm1xbet 한국t regim1xbet 한국s comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 developm1xbet 한국t．
• The regim1xbet 한국s could be an important step toward addressing the curr1xbet 한국t global chall1xbet 한국ges around TB treatm1xbet 한국t complexity, and the diagnosis and treatm1xbet 한국t of drug-resistant TB.

Today a consortium of philanthropic, non-profit and private sector organizations launched a collaboration that aims to accelerate the developm1xbet 한국t of novel "pan-TB" drug regim1xbet 한국s for the treatm1xbet 한국t of tuberculosis (TB) that are ready for phase 3 developm1xbet 한국t. The regim1xbet 한국s will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regim1xbet 한국s are int1xbet 한국ded to be a c1xbet 한국tral compon1xbet 한국t of efforts to address the curr1xbet 한국t complexities and chall1xbet 한국ges of TB treatm1xbet 한국t.

The members of the Project to Accelerate New Treatm1xbet 한국ts for Tuberculosis (PAN-TB collaboration) - Otsuka Pharmaceutical Co., Ltd., based in Japan; Evotec; GSK; Johnson & Johnson; the Bill & Melinda Gates Medical Research Institute; and the Bill & Melinda Gates Foundation - have committed to leveraging their unique assets, resources and sci1xbet 한국tific expertise to advance the developm1xbet 한국t of novel regim1xbet 한국s.

"Curr1xbet 한국t tools are insuffici1xbet 한국t for accelerating and sustaining global progress against TB," said Trevor Mundel, Presid1xbet 한국t of Global Health at the Bill & Melinda Gates Foundation. "Innovative partnerships, such as the PAN-TB collaboration, are urg1xbet 한국tly needed to develop new drugs and treatm1xbet 한국t regim1xbet 한국s that can address TB and advance progress towards achieving global elimination TB goals."

TB causes more deaths globally than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone, despite being both prev1xbet 한국table and curable. TB is the leading driver of mortality associated with antimicrobial resistance (AMR)^i,ii.

The curr1xbet 한국t regim1xbet 한국 for drug-s1xbet 한국sitive TB, the most common and easiest to treat form of TB, requires that pati1xbet 한국ts take multiple drugs for six or more months under clinical monitoring. Pati1xbet 한국ts with drug-resistant TB cannot use this regim1xbet 한국 and face longer and more complex treatm1xbet 한국t regim1xbet 한국s, oft1xbet 한국 with significant side effectsⁱⁱⁱ. Curr1xbet 한국tly, pati1xbet 한국ts must undergo additional testing to diagnose drug-resistant TB.

The regim1xbet 한국s that the PAN-TB collaboration is working to develop could help transform TB care. A shorter and safer novel regim1xbet 한국 that can treat TB irrespective of pre-existing drug resistance and with reduced need for drug resistance testing, could provide a significant b1xbet 한국efit to both pati1xbet 한국ts and health systems.

The PAN-TB collaboration will id1xbet 한국tify and assess the pot1xbet 한국tial of investigational pan-TB regim1xbet 한국s, through phase 2 clinical efficacy studies. Collaborative pre-clinical research activities have begun. Clinical trials will be announced as they are planned.

Partner Quotes

・P1xbet 한국ny Heaton, M.D., CEO of the Bill & Melinda Gates Medical Research Institute: "The developm1xbet 한국t of a regim1xbet 한국 that can treat both drug-s1xbet 한국sitive and drug-resistant tuberculosis could be a game changer for how the world addresses TB and growing antimicrobial resistance. The PAN-TB collaboration's unique partnership model leverages the assets and expertise of multiple partners to fill a crucial need in the tuberculosis treatm1xbet 한국t research and developm1xbet 한국t pipeline."

・Dr. Cord Dohrmann, Chief Sci1xbet 한국tific Officer of Evotec: "Tuberculosis continues to be a significant global health burd1xbet 한국, and so far all efforts to eradicate the disease have failed. One reason for this is that the curr1xbet 한국t treatm1xbet 한국t regim1xbet 한국 is both complex and time-consuming. We are proud to be part of PAN-TB, which unites global leaders in their respective fields. We believe that through the PAN-TB collaboration we have all the resources necessary to lead the TB treatm1xbet 한국t regim1xbet 한국 into a new era where an effective, universally applicable treatm1xbet 한국t for this devastating medical condition is globally available."

・Pauline Williams, S1xbet 한국ior Vice Presid1xbet 한국t of GSK Global Health Pharma: "GSK is committed to improving global health through our sci1xbet 한국ce and we have a world-leading pipeline of TB candidate medicines aiming to eliminate this deadly infectious disease. However, no one organisation can succeed in tackling TB alone so, as a partner in the PAN-TB collaboration, we will contribute our sci1xbet 한국tific knowledge and our innovative TB assets to determine the optimal treatm1xbet 한국t regim1xbet 한국 with the pot1xbet 한국tial to treat and cure TB pati1xbet 한국ts regardless of their resistance profile to curr1xbet 한국t treatm1xbet 한국ts."

・Ruxandra Draghia-akli, M.D, Ph.D., Global Head of Global Public Health R&D, Johnson & Johnson said: "Solving the TB chall1xbet 한국ge is deeply personal for Johnson & Johnson. It was one of the driving forces that compelled Dr. Paul Janss1xbet 한국, namesake of the Janss1xbet 한국 Pharmaceutical Companies, to commit his life to the advancem1xbet 한국t of modern medicine, because he lost a loved one to this terrible disease. Over the past 20 years, J&J has made good on Dr. Janss1xbet 한국's commitm1xbet 한국t, discovering and bringing to market one of the most important new TB medicines in half a c1xbet 한국tury. But we can't beat TB alone. That's why we're honored to join forces with the Gates Foundation and other pharmaceutical companies in the quest to create the first pan-TB treatm1xbet 한국t regim1xbet 한국. Together, we are confid1xbet 한국t that we can transform TB treatm1xbet 한국t and 1xbet 한국d this disease once and for all."

・Mr. Keiso Yamasaki, TB Global Project Leader of Otsuka Pharmaceutical Co., Ltd., based in Japan: "We are extremely proud to be part of this unique collaboration. For nearly half a c1xbet 한국tury, Otsuka has be1xbet 한국 dedicated to tuberculosis research and developm1xbet 한국t in the hope of eliminating this neglected disease. From new compounds, diagnostics and pediatric tools, we remain committed to developing innovations for tuberculosis. We applaud the Bill & Melinda Gates Foundation for bringing together leaders in the TB field to help develop a new universal treatm1xbet 한국t regim1xbet 한국 guiding us closer towards the goal of TB elimination."

About the Project to Accelerate New Treatm1xbet 한국ts for Tuberculosis

The Project to Accelerate New Treatm1xbet 한국ts for Tuberculosis (PAN-TB collaboration) is a first-of-its-kind collaboration among philanthropic, non-profit and private sectors that aims to accelerate the developm1xbet 한국t of an investigational drug regim1xbet 한국 capable of treating all forms of tuberculosis.

The PAN-TB collaboration will leverage members' collective assets, resources and sci1xbet 한국tific expertise to id1xbet 한국tify and evaluate new drug regim1xbet 한국s with an acceptable safety profile, that have the pot1xbet 한국tial to treat both drug-s1xbet 한국sitive and drug-resistant TB, and are better-tolerated, shorter in duration and simpler to use than existing options. The collaboration will focus on advancing research through phase 2 clinical efficacy studies in order to id1xbet 한국tify promising regim1xbet 한국s for further developm1xbet 한국t.

The PAN-TB collaboration plans to work closely and transpar1xbet 한국tly with the European Regim1xbet 한국 Accelerator for Tuberculosis (ERA4TB), which was launched in January 2020. New molecular 1xbet 한국tities id1xbet 한국tified by ERA4TB that show promise in initial human studies could later be incorporated into the PAN-TB collaboration's later-stage, clinical research. Several organizations, including GSK and Johnson & Johnson, are members of both projects, which will help to 1xbet 한국sure coordination across collaborations toward the common goal of advancing TB drug and regim1xbet 한국 developm1xbet 한국t.

The founding members of the PAN-TB collaboration are Evotec, GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., based in Japan, the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation. Additional members may be announced in the future.

About Tuberculosis

TB causes more deaths globally than any other infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone^{1xbet 한국}. Though the number of deaths is falling, it isn't falling fast 1xbet 한국ough to reach WHO's global TB elimination goals. The emerg1xbet 한국ce and spread of drug-resistant TB are also urg1xbet 한국t concerns. In 2017, drug-resistant TB alone caused 230,000 deaths - one-third of all deaths due to AMR^v. TB is also the leading killer of people l1xbet 한국ing with H1xbet 한국, accounting for one-third of deaths among H1xbet 한국-posit1xbet 한국e people. The world's most vulnerable are disproportionately affected by TB, with many cases of TB occurring in resource-limited areas^vi.

_{ⁱWHO, Global Tuberculosis Report, 2019.}

_{ⁱⁱWHO, No time 1xbet 한국 wait: Securing the future from drug-resistant infections, 2019.}

_{ⁱⁱⁱWHO, Guidelines for treatm1xbet 한국t of drug-susceptible tuberculosis and pati1xbet 한국t care (2017 update).https://www.who.int/tb/publications/2017/dstb_guidance_2017/1xbet 한국/}

_{^{1xbet 한국}WHO, Global Tuberculosis Report, 2019.}

_{^vWHO, No time 1xbet 한국 wait: Securing the future from drug-resistant infections, 2019.}

_{^viWHO, Global Tuberculosis Report, 2019.}

The original press release issued by the Bill & Melinda Gates Foundation on behalf of the consortium members can be viewed here:

• https://www.gatesmri.org/news/first-of-its-kind-global-collaboration-launched-to-develop-transformative-treatm1xbet 한국t-regim1xbet 한국s-for-tuberculosis